Genomics in containment: BSL-4-compatible workflows enable high-resolution genomic and transcriptomic analyses of Risk Group 4 viruses
Genomic research on high-consequence Risk Group 4 (RG4) viruses is significantly hindered by the stringent biosafety level 4 (BSL-4) containment requirements, because virus inactivation prior to removal from containment often compromises nucleic acid integrity. As a focused solution to retain nucleic acid integrity as well as safety compliance, we developed and validated a comprehensive suite of optimized workflows compatible with BSL-4 containment and next-generation sequencing applications. We systematically assessed inactivation, homogenization, and RNA extraction methods to establish robust bulk RNA sequencing workflows for diverse sample types. We also adapted state-of-the-art single-cell RNA sequencing (scRNA-seq) by integrating inactivation steps without compromising data quality. To demonstrate feasibility, we conducted scRNA-seq analysis on cells exposed to Lassa virus. Additionally, we optimized viral genome enrichment strategies for high-depth sequencing of multiple RG4 viruses. These validated workflows enable safe, reproducible, and high-resolution genomic analyses of RG4 pathogens, significantly expanding the experimental toolkit for BSL-4 research.
Authors
- Michael R. Holbrook (ORCID: https://orcid.org/0000-0002-0824-2667)
- Monika Mehta (ORCID: https://orcid.org/0000-0003-3928-3733)
- Andrew P. Platt (ORCID: https://orcid.org/0000-0001-8481-114X)
- Lirong Peng (ORCID: https://orcid.org/0009-0001-9586-3719)
- Shawn Hirsch
- Gregory Kocher
- David Drawbaugh
Institutions
- National Institutes of Health (US)
- National Heart, Lung, and Blood Institute (US)
- National Institute of Allergy and Infectious Diseases (US)
Publication Details
- Journal
- iScience
- Published
- 2026-07-23
- DOI
- https://doi.org/10.1016/j.isci.2026.116874
- Primary Topic
- interferon and immune responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases